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Abstract: Background Walnut is an important elicitor of food allergy in children and adults with a
high rate of severe reactions. Multicenter studies using a common clinical protocol and a comprehensive
allergen are lacking. Objective To investigate potential correlations between molecular sensitization
patterns and clinical characteristics of walnut-allergic patients. Methods A total of 91 walnut-allergic
subjects and 24 tolerant controls from Switzerland, Germany, and Spain were included. Walnut allergy
was established by food challenge in all but anaphylactic subjects. Specific IgE (sIgE) to walnut extract,
rJug r 1 (2S albumin), rJug r 3 (nonspecific lipid transfer protein 1), nJug r 4 (11S globulin), rJug r 5 (PR-
10 protein), 2 vicilin fractions, profiling, and cross-reactive carbohydrate determinant was determined by
ImmunoCAP. A threshold of 0.10 kUA/L was used for positivity. Results Sensitivity of sIgE to walnut
extract was 87% and increased to 96% for the sum of all walnut components. sIgE to walnut extract
and all walnut components, except rJug r 5, was significantly higher in patients younger than 14 years
at inclusion. Stratification by age at onset of walnut allergy led to similar results. All patients younger
than 14 years had severe reactions, whereas 38% of patients 14 years or older were mild reactors. Severe
reactors (n = 70) had higher sIgE levels than did mild reactors (n = 21) to walnut extract (P < .0001),
rJug r 1 (P < .0001), nJug r 4 (P = .0003), and both vicilin fractions (P < .0001), but not to Jug r 3
and Jug r 5. Conclusions Sensitization to walnut storage proteins is acquired in childhood and correlates
with severe reactions. sIgE levels to storage proteins Jug r 1 and Jug r 4 and vicilin fractions, but not to
nonspecific lipid transfer protein and PR-10 proteins, correlate with systemic reactions to walnut.
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Allergen recognition patterns in walnut allergy are age dependent and correlate with 1 
the severity of allergic reactions 2 
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Abstract  62 
Background: Walnut is an important elicitor of food allergy in children and adults with a high 63 
rate of severe reactions. Multicenter studies using a common clinical protocol and a 64 
comprehensive allergen are lacking.  65 
Objective: To investigate potential correlations between molecular sensitization patterns and 66 
clinical characteristics of walnut allergic patients. 67 
Methods: 91 walnut allergic subjects and 24 tolerant controls from Switzerland, Germany and 68 
Spain were included. Walnut allergy was established by food challenge in all but anaphylactic 69 
subjects. sIgE to walnut extract, rJug_r_1 (2S albumin), rJug_r_3 (nsLTP1), nJug_r_4 (11S 70 
globulin), rJug_r_5 (PR-10 protein), two vicilin fractions, profilin and CCD was determined by 71 
ImmunoCAP. A threshold of 0.10 kUA/L was used for positivity. 72 
Results: Sensitivity of sIgE to walnut extract was 87% and increased to 96% for the sum of all 73 
walnut components. sIgE to walnut extract and all walnut components, except rJug_r_5, was 74 
significantly higher in patients below 14 years of age at inclusion. Stratification by age at onset 75 
of walnut allergy led to similar results. All patients <14 years had severe reactions whereas 76 
38% of patients >14 years were mild reactors. Severe reactors (n=70) had higher sIgE levels 77 
than mild reactors (n=21) to walnut extract (p<0.0001), rJug_r_1 (p<0.0001), nJug_r_4 78 
(p=0.0003) and both vicilin fractions (p<0.0001), but not to Jug_r_3 and Jug_r_5.  79 
Conclusion: Sensitization to walnut storage proteins is acquired in childhood and correlates 80 
with severe reactions. sIgE levels to storage proteins Jug_r_1, Jug_r_4 and vicilin fractions, 81 
but not to nsLTP and PR-10 proteins, correlate with systemic reactions to walnut.  82 
 83 




Highlights box:  85 
1. What is already known about this topic? 86 
Walnut allergy is an important and prevalent tree nut allergy associated with severe 87 
allergic symptoms. 88 
2. What does this article add to our knowledge? 89 
The study provides information on the relative importance of all known walnut allergens 90 
across Europe and evidence suggesting that that vicilins may be as important as 2S 91 
albumin in walnut allergy.  92 
3. How does this study impact current management guidelines 93 
Patients with early onset walnut allergy have an elevated risk of severe reactions and 94 
should be given particular attention in the clinic.  95 
 96 
 97 
Key words: walnut, food allergy, component resolved diagnosis, food challenge, age, 98 
severity, vicilin 99 
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CCD cross-reactive carbohydrate determinant 113 
DBPCFC double-blind placebo-controlled food challenge 114 
sIgE  specific IgE 115 
SPT skin prick test 116 
CRD component resolved diagnostics 117 






Walnuts are seeds from the trees of Juglans genus, which consists of 24 different species. 121 
The Juglans regia species, the common or Persian walnut, is the most frequently consumed 122 
in Europe.  123 
According to data from the Europrevall project, 3% of the adult European population is 124 
predicted to be sensitized to walnut, ranging from 0.1% in Iceland to 6 and 8% in Switzerland 125 
and Spain, respectively (1). Among children and adolescents with anaphylaxis to tree nuts, 126 
walnut belonged to the most important elicitors, accounting for 16% of the cases (2). 127 
According to telephone interviews with almost 5000 random households in the US, walnut 128 
was the most common offending tree nut, reported as a trigger in 60% of tree nut allergic 129 
individuals (3). In Chile, a cross-sectional questionnaire-based study indicated that allergy to 130 
walnut was the most prevalent food allergy in school aged children (4).  131 
Threshold dose distribution data revealed that 3.1-4.1 mg walnut protein, corresponding to 132 
1/180 of a walnut kernel, elicited an allergic reaction in 5% of a walnut allergic population (5). 133 
Despite of the emerging importance of walnut allergy, there is a scarcity of data on the 134 
importance of individual walnut allergens.  135 
Allergens identified in walnut to date are the storage proteins Jug r 1 (2S albumin), Jug r 4 136 
(11S globulin), Jug r 2 and Jug r 6 (vicilins) and the non-specific lipid transfer protein (nsLTP) 137 
Jug r 3. Moreover, walnut allergens with cross-reactivity to pollen are known; mainly a 138 
profilin, Jug r 7, and the recently described Bet v 1 homologous protein Jug r 5 (6-12). Here 139 
we present data of the most comprehensive study to date on molecular sensitization patterns 140 
to all known and officially accepted walnut allergens (www.allergen.org) in patients with 141 
confirmed walnut allergy, including children and adults, patients from Mediterranean and 142 
from birch pollen exposed regions, with a particular focus on severity and age of 143 





Design and Methods 146 
Study design and subjects 147 
Four allergy clinics in Switzerland (CH, Zurich and Lucerne), Germany (DE, Bonn) and Spain 148 
(ES, Barcelona) participated in this prospective multi-centre study. The clinical part of the study 149 
took place between 2013 and 2017. The study was approved by each centre’s local ethical 150 
committee and all patients gave written informed consent before entering the study (KEK-ZH 151 
2012-0519, EKNZ-2015-368; CEIC-2012/7085; AEKNO-2013310.).  152 
In total, 115 individuals were included. All patients underwent the same clinical evaluation, 153 
including an extensive interview using a uniform questionnaire and blood sampling.  154 
Final inclusion criteria for the group of walnut allergic patients (n=91) were a positive food 155 
challenge (double-blind placebo-controlled challenge (DBPCFC) or an open titrated food 156 
challenge (OFC)) or a convincing case history of anaphylaxis following ingestion of walnut. 157 
Sixty-one patients with a suggestive case history of a walnut allergy were included after 158 
agreeing to a food challenge. The remaining 30 patients were included on the basis of a case 159 
history of an anaphylactic reaction, defined as severe life-threatening reaction such as drop 160 
of blood pressure, severe bronchospasm or laryngeal edema within two hours after ingestion 161 
of walnut without performing a food challenge. Atopic controls were recruited from CH (n=5), 162 
DE (n=3) and ES (n=6) and 10 non-atopic controls from CH (n=5) and ES (n=5). The atopic 163 
controls had a history of pollen allergy with a positive SPT and/or positive sIgE test to 164 
relevant pollen allergens and were tolerant to walnut. The non-atopic controls had no history 165 
of pollen or food allergy and negative skin prick tests (SPT) and/or sIgE tests to a panel of 166 
food and inhalant allergens.  167 




Food challenges 169 
Open titrated food challenges and DBPCFCs were performed according to a common 170 
protocol and consisted of the patient ingesting increasing doses of walnuts (5mg, 10mg, 171 
50mg, 100mg, 1.0g, 5.0g, 8.0g). A detailed description of the procedure is provided in this 172 
article’s Online Repository at www.jaci-inpractice.org. For the purposes of the study, each 173 
patient was attributed to one of the following four clinical reaction groups: group 1: patients 174 
with isolated subjective oral symptoms under provocation (OAS); group 2: patients with an 175 
“extended OAS” under provocation (OAS with either blisters of the oral mucosa, mild rhinitis 176 
or conjunctivitis, slight swelling of the lips, mild tightness of the throat or mild dysphagia); 177 
group 3: objective systemic reactions under provocation; group 4: history of anaphylaxis.  178 
 179 
Specific IgE antibody measurements 180 
For all patients and controls, serum sIgE to walnut, rJug r 1, rJug r 3, nJug r 4, rJug r 5, high 181 
and low molecular weight walnut vicilin fractions, rPru p 3, rBet v 1, rBet v 2 and CCD was 182 
determined by ImmunoCAP. Additionally, sIgE to rPla a 3 was determined in the Spanish 183 
patients and controls. sIgE values >0.1 kUA/L were considered positive. Purification of nJug r 184 
4 and high and low molecular weight vicilin fractions from walnut, generation of rJug r 5 and 185 
of experimental ImmunoCAP tests is described in this article’s Online Repository at 186 
www.jaci-inpractice.org.  187 
 188 
Skin testing 189 
Prick-to-prick tests (PTP) with native walnuts were performed in all walnut allergic patients 190 
and skin prick tests (SPT) with walnut extract (ALK-Abello, Madrid, Spain) in Swiss and 191 






Differences between clinical reaction groups (mild vs. severe reactors) and between age 195 
groups (<14 years of age vs. ≥14 years of age) with respect to mean sIgE concentration 196 
were evaluated with Two-Sample Wilcoxon Test. For frequencies, Fisher’s exact test was 197 
used. 198 
A logistic regression model was applied with clinical severity (occurrence of systemic 199 
reactions) as dependent variable and sex, age at inclusion into study (younger / older than 200 
14 years), age at onset of walnut allergy (younger / older than 14 years), geographical region 201 
(Switzerland and Germany versus Spain), and sensitization to walnut components 202 
(below/equal or above threshold 0.10 kUA/L) as independent variables. Additionally, data was 203 
evaluated with univariate logistic regression models. The statistical analysis was performed 204 









Patients’ characteristics and food challenges 211 
Overall, 91 walnut allergic patients were enrolled, 31 adolescents and adults from CH (22 212 
females (f), 9 males (m), age 34±12 years (y), range 15-68 y), 31 from DE (15 f, 9 m, age 6±3 213 
y, range 2-15 y) and 29 from ES (15 f, 14 m, age 32±16 y, range 3-53 y). Fifteen patients were 214 
included on the basis of a positive DBPCFC (DBPCFC+ve), 46 patients on a positive titrated 215 
oral food challenge (OFC+ve) and 30 patients on a positive case history of walnut induced 216 
anaphylaxis. Furthermore, 14 atopic controls with pollen allergy and a history of walnut 217 
tolerance and 10 non-atopic controls were analysed. In 60 patients (68%), the onset of walnut 218 
allergy was before their 14th birthday.  219 
Sixteen challenge positive patients (18%) reported an isolated OAS under provocation and five 220 
an extended OAS with mild additional symptoms of the lips or throat, or rhinoconjunctivits, and 221 
40 patients developed a systemic reaction, 75% with skin symptoms such as flush, urticaria, 222 
angioedema, 33% with respiratory symptoms, 23% with gastrointestinal symptoms and 8% 223 
with laryngeal involvement. Table E1 summarizes the clinical reactivity of all included walnut 224 
allergic patients. Allergic reactions to the following tree nuts were reported by the 91 walnut 225 
allergic subjects: pecan nut (9%), hazelnut (44%), almond (18%), brazil nut (13%), cashew 226 
(11%), pistachio (13%) and macadamia (8%). 227 
 228 
Sensitization to walnut extract and individual allergens 229 
PTP was positive in all tested walnut allergics from Spain and Germany (n=51) and in 13 out 230 
of 27 Swiss patients (overall sensitivity 82%) whereas SPT with walnut extract was positive in 231 
25/29 Spanish patients and in 17/30 Swiss patients (overall sensitivity 71%). For serum sIgE 232 
testing the threshold for positivity was set to 0.10 kUA/L. This cut-off was selected on the basis 233 
of a ROC analysis for sIgE to walnut extract, providing a sensitivity of 98.6% (95% Confidence 234 
Interval (CI): 92.3%-100%) and a specificity of 52.4% (95% CI: 29.8%-74.3%) for diagnosing 235 




Considering the entire walnut allergic population, the sensitivity of sIgE to walnut extract was 237 
87%, whereas 96% were sensitised to at least one walnut component. In patients with mild 238 
symptoms (group 1 and 2) sensitivity of sIgE measurement to walnut extract was particularly 239 
compromised and as low as 48%. Eight of eleven patients with mild symptoms but no sIgE to 240 
walnut extract were sensitised to the Bet v 1 homologous protein rJug r 5. Thus, only rJug r 5 241 
accounted for the increased sensitivity of component testing compared to the whole walnut 242 
extract. Four patients, three with mild symptoms and one with anaphylaxis, tested negative to 243 
walnut extract and did not recognize any of the included components. In total, 53% of walnut 244 
allergic subjects were sensitized to rJug r 1, 53% to rJug r 3, 48% to nJug r 4, 52% to rJug r 5, 245 
57% to nJug r vicilin-H, 73% to nJug r vicilin-L, 17% to profilin (rBet v 2) and 19% to CCD. The 246 
concentration of IgE to the single walnut allergens is summarized in Figure 1.  247 
 248 
Sensitization profile in atopic and nonatopic controls 249 
All nonatopic controls tested completely negative to walnut extract and allergens. Five Swiss 250 
and one German atopic controls were sensitized to rJug r 5 and all presented relatively high 251 
levels of sIgE to rBet v 1. Three Spanish and two German atopic controls were sensitised to 252 
rJug r 3, four of them to rPru p 3 and one to rPla a 3 at higher concentrations. Sensitisation to 253 
rJug r 1 (3/3 patients) and nJug r 4 (1/3 patients) was only observed in the three German 254 
pediatric atopic controls. Sensitisation rates to nJug r Vicilin-H and nJug r Vicilin-L among the 255 
atopic controls were 43% and 36%, respectively. Since the number of controls was limited, 256 
specificity in relation to the controls was not calculated.  257 
 258 
Geographic differences in sensitization pattern   259 
Figure 2 summarizes the sensitization pattern of patients from the three geographic regions to 260 
walnut extract and the single allergen components. Particularly prominent differences were 261 
observed for sensitization to rJug r 3, which was higher in ES than in CH and DE and for rJug 262 




nJug r 4 were observed than in CH and ES, but this finding was confounded by the fact that in 264 
DE, a purely pediatric population was recruited.  265 
 266 
Age dependency of the sensitization pattern to walnut allergens 267 
Mean concentrations of sIgE to walnut extract and all walnut components except rJug r 5 were 268 
significantly higher in walnut allergic patients below 14 years of age than in those above that 269 
age at inclusion into the study. Also, if stratified by the age of walnut allergy onset, patients 270 
who acquired walnut allergy before the age of 14 had significantly higher sIgE concentrations 271 
to walnut extract and all walnut allergens except for rJug r 3 (p< 0.0001 for rJug r 1, nJug r 4, 272 
nJug r vicilin-H and nJug r vicilin-L, p<0.01 for walnut extract, p<0.05 for rJug r 5) than those 273 
with later onset (Table 1). Among the late onset reactors, only three subjects were sensitised 274 
to rJug r 1 (11%), two to nJug r 4 (7%) and six to nJug r vicilin-H (21%), whereas sensitisation 275 
rates to these storage proteins were significantly higher in the early onset allergics (75%, 70% 276 
and 77%, respectively, Figure 3), supporting the view that sensitisation to these storage 277 
proteins is primarily acquired during childhood.  278 
Of the early onset allergics, 90% belonged to the severe reactors (group 3/4) whereas 46% of 279 
the late onset allergics belonged to the mild reactors (group 1/2). Thus, age at onset of allergy 280 
to walnut (<14 years vs ≥14 years) significantly correlated with the severity of the clinical 281 
reaction (p=0.0002; Fisher’s exact test). If stratified by age at inclusion into the study, similar 282 
results were observed (p<0.0001; Fisher’s exact test). 283 
 284 
Are there any predictive markers for the severity of the clinical reaction? 285 
Patients of clinical reaction groups 3/4 (severe reactors: n=70; systemic reaction under 286 
challenge or anaphylaxis) had significantly higher concentrations of sIgE to walnut extract 287 
(p<0.0001), rJug r 1 (p<0.0001), nJug r 4 (p<0.0001), nJug r vicilin-L (p=0.0001), and nJug r 288 
vicilin-H (p<0.0001) than patients of clinical reaction groups 1/2 (mild reactors: n=21; 289 




mucosa under challenge). No significant differences between these groups were found for sIgE 291 
to rJug r 3 and rJug r 5 (Table 2). Nevertheless, when stratified for geographic regions (CH/DE 292 
versus ES), significant differences between mild and severe reactors for sIgE concentrations 293 
to walnut extract, rJug r 1, nJug r 4, nJug r vicilin-L and nJug r vicilin-H were found among the 294 
Swiss and German walnut allergic patients but not among the Spanish patients. Thus, the level 295 
of sensitisation to all analysed walnut allergens did not differ between mild and severe reactors 296 
from Spain. 297 
Sensitisation to rJug r 1 and nJug r 4 was only observed among the severe reactors (Figure 298 
4). Furthermore, the sensitisation rate to nJug r vicilin-H and vicilin-L was much higher in the 299 
severe reactors than in the mild reactors (71% vs 10% and 84% vs 33%, respectively). 300 
Symptom severity (group 3/4, severe reactors vs group 1/2, mild reactors) was highly 301 
significantly (p<0.0001; Fisher’s exact test) associated with sensitisation to walnut extract, rJug 302 
r 1, nJug r 4, nJug r vicilin-L and nJug r vicilin-H but not with sensitisation to rJug r 3 and rJug 303 
r 5. Results were consistent when applying a cut-off level for positivity of 0.35 rather than 0.10 304 
kUA/L. 305 
Logistic regression revealed a significant influence of sensitization to walnut extract and to 306 
both vicilin fractions, as well as the age of onset of walnut allergy, on the severity of the 307 
clinical reaction. However, since all patients included into the study at an age <14 years and 308 
all patients sensitized to rJug r 1 belonged to the severe reactors, the odds ratio for 309 
developing a severe reaction could not be calculated (not determinable). In the logistic 310 
regression analysis, gender, geographic region and sensitisation to rJug r 3, nJug r 4 and 311 
rJug r 5, all showed no influence on clinical severity (p>0.05).  312 
The risk of developing a systemic reaction was significantly higher for walnut extract 313 
sensitized patients (odds ratio (OR): 76.9; 95% CI: 8.7-500, p<0.0001), for nJug r vicilin-L 314 
and vicilin-H sensitised patients (OR: 10.5 and 23.3, CI: 3.5-32.3 and 5.0-111, respectively, 315 




7.655, CI: 2.487-23.563; p=0.0004) than for patients not sensitized to walnut extract, neither 317 







To our knowledge, this study represents the most comprehensive CRD analysis done in walnut 322 
allergic children and adults so far.  We quantified specific IgE concentrations to walnut 323 
allergens in 91 European walnut-allergic pediatric and adult individuals recruited in three 324 
countries, Germany, Switzerland and Spain, as well as in 24 walnut tolerant controls.  325 
 326 
For serological analysis, a cut-off of 0.10 kUA/L was used for sIgE positivity, but the majority of 327 
results, in particular on age dependency and severity, remained stable when the analyses were 328 
repeated with a cut-off of 0.35 kUA/L.  329 
 330 
Specific IgE to walnut extract showed a sensitivity of 87% which increased to 96% when sIgE 331 
to the Bet v 1 homologue Jug r 5 was taken into consideration. However, at the same time this 332 
led to a reduction of diagnostic specificity as six of the 14 atopic controls (43%) also showed 333 
positive test results to Jug r 5. As the size of our atopic and non atopic control groups were 334 
limited, an extended statistical analysis of our patient group data in comparison to the controls 335 
was not performed. However, the data appear to be in accordance with other CRD studies in 336 
plant food allergy (13-15), showing very high specificity in comparison to non allergic controls 337 
and negative effects on specificity caused by cross-reactivity of sIgE to Bet v 1 with PR-10 338 
allergens from foods in pollen allergic patients without food allergy. Notably, we found little 339 
effect on diagnostic performance by sensitization to profilin and CCD, as the sensitization rates 340 
among the walnut allergic patients were below 20% and only 2 and 3 atopic controls were 341 
positive to these allergen components, respectively. 342 
 343 
Sensitivity of PTP and SPT with native walnuts and the commercial walnut extract, 344 
respectively, was particularly affected in the CH population (48% and 57%), which can be 345 
most likely explained by a low content of Bet v 1 homologous proteins in tree nuts and a 346 




Our data analysis revealed statistically significant differences between patients with mild 348 
symptoms (groups 1 and 2) and more severe / systemic symptoms (groups 3 and 4) on the 349 
one hand, and between patients below versus above 14 years of age on the other hand.  350 
 351 
Geographic differences observed in our study need to be considered in view of the fact that 352 
the patient populations recruited in the different study centers were not fully comparable in 353 
terms of age. In Spain, adults/adolescents as well as children were included; in Switzerland 354 
the youngest patient was 15 years-old at inclusion, whereas in Germany only children up to 15 355 
years of age were included, the majority being below 10. Keeping in mind these differences, 356 
we found the highest sensitization rate to the nsLTP Jug r 3 in Spain, whereas sensitization to 357 
the Bet v 1 homologue Jug r 5 was much more common in Switzerland and Germany. This 358 
observation is in full accordance with other studies describing a predominance of nsLTP 359 
sensitization in plant food allergy in southern Europe, as well as a dominating role of Bet v 1 360 
related food allergens in birch endemic regions, such as Switzerland, Germany and 361 
Scandinavia (reviewed in 16-17). Moreover, higher sensitization rates to the storage proteins 362 
Jug r 1 (2S albumin) and Jug r 4 (11S globulin) were found in the German patient population. 363 
This finding reflects a more prominent role of the storage proteins in paediatric subjects with 364 
primary sensitization to walnuts.  365 
 366 
Concerning age dependency, all patients <14 years of age had severe reactions (group 3/4), 367 
as compared to 62% of patients >14 years of age. In regard to serology, we found significantly 368 
higher mean levels of sIgE to walnut extract and Jug r 1, Jug r 3, Jug r 4, and the two vicilin 369 
preparations in patients below 14 years of age at inclusion versus patients above 14 years. 370 
When stratified for age of allergy onset, similar results were obtained, except that the difference 371 
was not significant for Jug r 3 (p=0.0985), but turned significant for Jug r 5 (p=0.0368) (Table 372 
1). The frequency of detectable sIgE (regardless of level) was also different between late and 373 




being significantly more frequent in early onset allergics (Figure 3). 375 
Taken together, our data on age dependency of sensitization patterns are comparable to 376 
findings obtained in peanut allergic patients recruited within the EuroPrevall study (18).  377 
 378 
We also analysed a potential correlation of sIgE levels with severity of clinical reactions to 379 
walnut. Mean sIgE concentrations to walnut extract and all walnut allergens except Jug r 3 and 380 
Jug r 5 were significantly higher in clinical reaction groups 3/4 than in groups 1/2. Similar to 381 
reports in peanut allergy (18-20) and hazelnut allergy (21), this result supports the view that 382 
severe reactions to legume seeds and nuts are predominantly caused by sensitization to 383 
storage proteins rather than by pollen related allergens such as Bet v 1 homologues, or nsLTP. 384 
A plausible explanation for this phenomenon could be the relatively low content of Bet v 1 385 
related proteins and nsLTP in such high protein containing foods, leading to a lower allergen 386 
intake in comparison to storage proteins which are present in much higher amounts.  387 
Interestingly, no significant differences in sIgE concentrations between symptom groups 3/4 388 
versus groups 1/2 were detected in the Spanish patients. While it is clear that this phenomenon 389 
cannot be explained by clinically insignificant sIgE binding to cross-reactive components such 390 
as PR-10 allergens, profilin, or nsLTP, it is difficult to establish a plausible hypothesis. We 391 
speculate that the more complex allergen environment in Spain in comparison to Switzerland 392 
and Germany may play a role, but a separate study will be required to confirm this finding and 393 
address potential reasons. 394 
The two vicilin preparations used in this study showed a high frequency of sIgE binding (56% 395 
and 71% for vicilin-H and vicilin-L, respectively). These rates are the highest of all purified 396 
allergen preparations used in this study, suggesting that Jug r 2 and/or Jug r 6 may become 397 
important additions to the panel of allergens used in the diagnosis of walnut allergy.  398 
In summary, our study showed that the sensitivity of sIgE testing in walnut allergy can be 399 
increased by component resolved diagnosis and that this increase is mainly related to the Bet 400 




storage proteins is usually acquired in childhood and is associated with severe allergic 402 
reactions. IgE to storage proteins Jug r 1, Jug r 4 and vicilin fractions, but not to nsLTP and 403 
PR-10 proteins, is significantly associated with systemic reactions to walnut. Provided that 404 
these findings are confirmed by further studies in well-characterised patients with food allergy 405 
to walnut, sIgE to these storage proteins may come to serve as a marker for an increased risk 406 






Legends to figures 410 
 411 
Figure 1: 412 
IgE concentration to walnut extract and to the different walnut allergen components in all 413 
walnut allergic patients and in patients from CH, ES, DE. IgE to profilin and CCD is not 414 
included, but described in the text. Numbers in brackets indicate the number of observations 415 
below the 0.1 kUA/L cut-off. Horizontal bars: median; dotted line: cut-off. 416 
 417 
Figure 2: 418 
Percentage of patients with sensitization to walnut extract and to the different components in 419 
walnut allergic patients from CH, ES, DE. 420 
 421 
Figure 3: 422 
Percentage of patients with sensitization to walnut extract and to the different components in 423 
subjects with onset of walnut allergy before their 14th birthday and beyond the age of 14 424 
years. 425 
 426 
Figure 4: 427 
Percentage of patients with sensitization to walnut extract and to the different components in 428 
walnut allergic patients with severe reactions (group 3/4, systemic reaction under provocation 429 
or anaphylaxis by history) and mild reactors (group 1/2, with mild symptoms under 430 
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